BRIEF published on 12/09/2025 at 14:55, 6 months ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 6 months ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 6 months ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 6 months 28 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 6 months 28 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 7 months 4 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 7 months 4 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 7 months 30 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 7 months 30 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 8 months 22 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 06/10/2026 at 00:00, 1 hour 40 minutes ago Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Published on 06/09/2026 at 23:00, 2 hours 40 minutes ago NXT Energy Solutions Inc. Announces Results of Annual Meeting of Shareholders
Published on 06/09/2026 at 22:30, 3 hours 10 minutes ago Gamma Resources Announces Receipt of $604,500 from Warrant Exercises
Published on 06/09/2026 at 21:45, 3 hours 55 minutes ago Northfield Announces Change of Corporate Name to Juno International Corporation
Published on 06/09/2026 at 15:00, 10 hours 40 minutes ago Worksport Ltd. Reports Additional $50,000 CEO Insider Stock Acquisition, Reinforcing Confidence in Long-Term Value Creation
Published on 06/09/2026 at 22:55, 2 hours 45 minutes ago JACOBS STEPS-UP AS 'OFFICIAL SPONSOR OF STAYING AWAKE' AS SCHEDULE REVEALS SUMMER MATCH TIMES WILL PUSH EUROPEAN FOOTBALL FANS TO THE LIMIT
Published on 06/09/2026 at 22:35, 3 hours 5 minutes ago Eurobattery Minerals publishes Annual Report 2025
Published on 06/09/2026 at 19:32, 6 hours 7 minutes ago 2CRSi SA: 2CRSi announces a €110 million sale of Godì Blackwell Ultra servers in Germany
Published on 06/09/2026 at 19:10, 6 hours 29 minutes ago The 2026 Global Energy Prize shortlist released
Published on 06/09/2026 at 19:10, 6 hours 29 minutes ago THE SULTANATE OF OMAN CONSOLIDATES ITS POSITION AS A STABLE DESTINATION FOR GLOBAL CAPITAL
Published on 06/09/2026 at 19:30, 6 hours 10 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 06/09/2026 at 18:14, 7 hours 26 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2026
Published on 06/09/2026 at 15:17, 10 hours 23 minutes ago Statement of transactions in own shares from June 1, 2026 to June 5, 2026
Published on 06/09/2026 at 10:37, 15 hours 3 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from June 1 to June 5 2026
Published on 06/09/2026 at 07:00, 18 hours 40 minutes ago New strategic Milestone for Biophytis: Official Establishment of Its Joint Venture in Asia
